LianBio competitors and similar companiesClear all

LianBio's competitors and similar companies include OncoArendi Therapeutics, Xilio Therapeutics, Rakuten Medical and MolMed.
LianBio
LianBio
LianBio is a biopharmaceutical company that designs and provides innovative drugs and treatments for oncology and cardiology diseases.
OncoArendi Therapeutics
OncoArendi Therapeutics
OncoArendi Therapeutics is a biotech company focused on discovery and development of small molecule drug candidates.
Xilio Therapeutics
Xilio Therapeutics
Xilio Therapeutics (formerly Akrevia Therapeutics) is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics.
Rakuten Medical
Rakuten Medical
Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.
MolMed
MolMed
MolMed is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies.
Founding Date
Founding Date
2019
Founding Date
2012
Founding Date
2015
Founding Date
2013
Founding Date
1996
Type
Type
Public
Type
Private
Type
Private
Type
Private
Type
Public
Tags
Locations
Locations
Princeton, US HQ
Shanghai, CN
Locations
Warszawa, PL HQ
Łódź, PL
Locations
Waltham, US HQ
Locations
San Diego, US HQ
Setagaya City, JP
Amsterdam, NL
Ecublens, CH
Taipei, TW
Taipei, TW
San Mateo, US
Locations
Milano, IT HQ
Bresso, IT
Employees
Employees
87
Employees
652% increase
Employees
69
Employees
1671% decrease
Employees
186
Valuation ($)
Valuation ($)
214.5 m
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
279.3 m
Twitter followers
Twitter followers
N/A
Twitter followers
1.1 k
Twitter followers
230
Twitter followers
N/A
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
7
Number of tweets (last 30 days)
1
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
11.7
Average likes per tweet (last 30 days)
7
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
487397
Alexa Website Rank
N/A
Alexa Website Rank
469023
Alexa Website Rank
162644
Alexa Website Rank
732869
Employee Rating
Employee Rating
5
Employee Rating
N/A
Employee Rating
5
Employee Rating
2.1
Employee Rating
2.1

Financial

Net income
Net income
($196.3m) (FY, 2021)
Net income
N/A
Net income
($75.8m) (FY, 2021)
Net income
N/A
Net income
(€427k) (FY, 2019)

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 95m (over 1 year ago)
Latest funding round
$ 100m (about 3 years ago)
Latest funding round
N/A
Total funding raised
Total funding raised
$ 310m
Total funding raised
N/A
Total funding raised
$ 233m
Total funding raised
$ 451.9m
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

OncoArendi Therapeutics
HQ
Warszawa, PL
Employees
65↑ 2% increase

OncoArendi Therapeutics is a biotech company focused on discovery and development of small molecule drug candidates.

View company
Xilio Therapeutics
HQ
Waltham, US
Employees
69

Xilio Therapeutics (formerly Akrevia Therapeutics) is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics.

View company
Rakuten Medical
HQ
San Diego, US
Employees
167↓ 1% decrease

Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.

View company
MolMed
HQ
Milano, IT
Employees
186

MolMed is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies.

View company